GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Cash Flow for Lease Financing

Imugene (ASX:IMU) Cash Flow for Lease Financing : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Imugene Cash Flow for Lease Financing?

Imugene's Cash Flow for Lease Financing for the six months ended in Dec. 2023 was A$0.00 Mil. Imugene's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Compared with last quarter (A$0.00 Mil in Jun. 2023 ), Imugene's Cash Flow for Lease Financing remained the same in Dec. 2023 (A$0.00 Mil).

Imugene Cash Flow for Lease Financing Historical Data

The historical data trend for Imugene's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Cash Flow for Lease Financing Chart

Imugene Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imugene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Imugene Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Imugene's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Cash Flow for Lease Financing
Comparable Companies
ASX:OPT ASX:LTP ASX:PYC ASX:RAC ASX:IMM ASX:DXB ASX:ALA ASX:BOT ASX:RCE ASX:PIQ OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
IUGNF:USA
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines